title: Multi-Hospital Eastern Atlantic Restenosis Trial. II: A placebo-controlled trial of thromboxane blockade in the prevention of restenosis following coronary angioplasty.
abstract: Since platelet interactions appear to play an important role in the development of restenosis, attenuation of thromboxane-mediated reactions may improve the long-term outcome following coronary angioplasty. Phase II of the Multi-Hospital Eastern Atlantic Restenosis Trial (M-HEART) is a prospective, randomized, placebo-controlled study of thromboxane blockade in the prevention of restenosis following successful coronary angioplasty. Two forms of thromboxane blockade are evaluated: aspirin (a nonspecific inhibitor of thromboxane synthesis) and sulotroban (a specific thromboxane receptor antagonist). The design of this multicenter trial and the rationale for use of sulotroban in the prevention of restenosis are reviewed in this report.
authors.affiliation: Cardiac Catheterization Laboratory, Thomas Jefferson University Hospital, Philadelphia, PA 19107.
authors.forename: M P
authors.initials: MP
authors.lastname: Savage
authors.forename: S
authors.initials: S
authors.lastname: Goldberg
authors.forename: R G
authors.initials: RG
authors.lastname: Macdonald
authors.forename: T A
authors.initials: TA
authors.lastname: Bass
authors.forename: J R
authors.initials: JR
authors.lastname: Margolis
authors.forename: H B
authors.initials: HB
authors.lastname: Whitworth
authors.forename: A S
authors.initials: AS
authors.lastname: Taussig
authors.forename: G
authors.initials: G
authors.lastname: Vetrovec
authors.forename: M
authors.initials: M
authors.lastname: Cowley
authors.forename: A A
authors.initials: AA
authors.lastname: Bove
mesh_terms: D015906:Angioplasty, Balloon, Coronary; D001241:Aspirin / Q000627:therapeutic use; D017023:Coronary Angiography; D003327:Coronary Disease / Q000000981:diagnostic imaging / Q000453:epidemiology / Q000517:prevention & control* / Q000628:therapy; D004311:Double-Blind Method; D005500:Follow-Up Studies; D006801:Humans; D008873:Mid-Atlantic Region / Q000453:epidemiology; D010919:Placebos; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011446:Prospective Studies; D011982:Receptors, Prostaglandin / Q000187:drug effects*; D017482:Receptors, Thromboxane; D012008:Recurrence; D013449:Sulfonamides / Q000627:therapeutic use; D013931:Thromboxanes / Q000037:antagonists & inhibitors*
chemical_list: D010919:Placebos; D010975:Platelet Aggregation Inhibitors; D011982:Receptors, Prostaglandin; D017482:Receptors, Thromboxane; D013449:Sulfonamides; D013931:Thromboxanes; C040624:sulotroban; D001241:Aspirin